Bombesin antagonists

A compound of formula (I):

• 395
• wherein
• R1 is selected from
• a) aryl
• b) aromatic heterocycle
• c) CO2R5
• d) CONR5R6
• e) NR5R7
• f) OR5
• g) C1-6 alkyl
• h) C1-6 cycloalkyl and
• i) —C(O)—N-morpholine
• Wherein group (a) may be optionally substituted by 1-3 groups each independently selected from NR5R5, N(R5)C(O)R5, NO2, halo, OR5, R5 and R4NR5R5;
• and group (b) may be optionally substituted by 1-3 groups each independently selected from halo, R5 and OR5;
• m is 0-2;
• n is 0-2;
• p is 0-2;
• q is 0-2;
• r is 0-4
• Y is NR3 or CHR3;
• R2 is selected from
• a) C3-7 cycloalkyl,
• b) aromatic heterocycle, optionally fused with a phenyl group,
• c) aryl, wherein said aryl group may optionally be fused with a heterocycle or a C3-7 cycloalkyl group, wherein said fused cycloalkyl moiety may also incorporate a C═O group,
• d) Oaryl,
• e) C1-6 alkyl,
• f) Adamantyl, and
• g) C1-6 alkenyl, optionally substituted by 1 or 2 phenyl,
• wherein groups (a), (b), (c), (d) and (e) may be optionally substituted by 1-3 substituents selected from:
• R5, C1-6 alkenyl, aryl, OR4, OR5, OH, CF3, halo, SO2R5, NO2, SR5, CN, OCF3, CO2R5, C(O)R5, Oaryl, OR aryl, R4OR5, C(NH)NR5R5, OC(O)C1-6alkyl and NR5R7;
• R3 is selected from
• a) C1-6 alkyl,
• b) C1-6 alkenyl,
• c) C1-6 alkynyl,
• d) Aromatic heterocycle, optionally fused with phenyl,
• e) Phenyl, optionally fused with phenyl, heterocycle or aromatic heterocycle,
• said groups (a), (b), (c), (d) and (e) optionally substituted by 1-3 groups each independently selected from halo, CN, SR5, heterocycle, aromatic heterocycle, R5, OR7, C(O)NR5R7, SO2NR5R7, NHSO2R5, OH, CF3, OR5, OR5OR5, NR5R7, CO2H, CO2R5, OC(O)R5, C3-7 cycloalkyl group (wherein said cycloalkyl group may optionally be substituted by C1-6 alkyl), CH2OC(O)CH3 and phenyl, wherein said phenyl may optionally be fused with a heterocycle, aromatic heterocycle, phenyl or C3-7 cycloalkyl, said phenyl, fused phenyl, or aromatic heterocycle optionally substituted by 1-3 groups each independently selected from:
• phenyl, R4, CN, OH, OR4Ph, OR4CO2R5, C1-6 alkynyl, R4OC(O)R5, R4SR5, OC(O)R5, CF3, OR7, OR4OR5, CO2R5, OR4, CO2R5, HNC(O)R5, C1-6 alkenyl, OCF3, NO2, halo, HNSO2R5, SO2NR5R5, C(O)NR5R5, C(NH)NR5R5, OR5, OC(O)R4-heterocycle, NR5R7, SR5 and tetrazole;
• R4 is C1-6 alkyl;
• R5 is independently selected from H and C1-6 alkyl, said alkyl groups optionally substituted by 1-3 groups each independently selected from halo or OH;
• R6 is independently selected from H, heterocycle, OC1-6 alkyl, C1-6 alkyl, said alkyl groups optionally substituted by 1-3 groups each independently selected from halo or OH;
• or R5 and R6 can be taken together with the N atom to which they are attached to form a 5, 6 or 7-membered ring optionally containing a further hetero moiety selected from O, NH, or S;
• R7 is selected from H and C1-6 alkyl said alkyl groups optionally substituted by an aryl group;
• and
• R8 and R9 are both independently selected from H or C1-6 alkyl;
• or R8 and R9 may combine to form a 3-7 membered cycloalkyl group. Optionally said cycloalkyl group may incorporate an atom or group selected from NR4, NH, O or S;
• With the proviso that when R is an aryl or aromatic heterocycle group, R2 is a phenyl, pyridyl or pyrimidinyl group, said groups optionally substituted, R8 and R9 combine to form a 3-7 membered cycloalkyl group, Y is NR3 and m, p, q and r are 0;
• then R3 cannot be C4-6 alkyl or C1 alkyl substituted by phenyl, said phenyl group optionally substituted by 1-3 groups each independently selected from halo, OC1-6 alkyl and NR5R7;
• and the pharmaceutically acceptable salts, prodrugs, solvates thereof.